CAMBRIDGE, Mass., Jul 24, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2007, and the Company provided a pipeline update. "Vertex achieved its major development pipeline milestones in the first
<i>- Telaprevir Phase 3 registration program in hepatitis C on track;
NDA submission anticipated in second half of 2010 -</i><br /><i>- Vertex advancing two drug candidates aimed at the underlying
disease mechanism of the orphan disorder cystic fibrosis -</i><br /><i>- Vertex ends second quarter with $754 million of cash, cash
equivalents and marketable securities; Vertex will add to this position
with $105 million of cash through an amended agreement with Mitsubishi
Tanabe Pharma Corporation -</i><br />
<i>-Hepatitis C: Rolling submission of New Drug Application underway;
data from second pivotal Phase 3 trial - REALIZE - expected in the third
quarter of 2010-</i>
<br />
<i>-Cystic Fibrosis: Phase 3 registration program for VX-770 fully
enrolled; data expected in first half of 2011-</i>
<br />
<i>-Financial: Vertex ends second quarter with cash position of
approximately $980 million-</i>
<br />
Vertex Pharmaceuticals Reports Third Quarter 2001 Financial Results Cambridge, MA, October 24, 2001 — Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) reported consolidated financial results today for the three and nine months ended September 30, 2001.
Vertex Pharmaceuticals Reports Third Quarter 2007 Financial Results and Provides Development Pipeline Update Important telaprevir data to be presented at AASLD Additional compounds for HCV and Cystic Fibrosis scheduled to enter development Cambridge, MA, October 29, 2007 Vertex
